NOVARTIND
Small CapNovartis India Limited
Pharma
Novartis India Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is supportive, timing is unclear, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Technical trend unavailable.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Bad · 0/100PAT -14% YoY · margin compression · Rev +8% YoY · +6% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹91 Cr | +8.3% | +5.8% |
| EBITDA | ₹21 Cr | -12.5% | -4.5% |
| Operating margin | 23.0% | -600 bps | -300 bps |
| PAT | ₹25 Cr | -13.8% | +56.3% |
| PAT margin | 27.5% | -705 bps | +887 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Novartis India Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
Trend score is pending. The candlestick chart remains available for manual review.
Technical chart
NOVARTINDweekly · 1Y+38.4%Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 7/9.
- Fair-value margin of safety is positive at 16.0%.
- Balance sheet contributes 13/15 to the score.
Main drags
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Valuation is weaker at 5/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 87th percentile of the scored universe and 82nd percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 70.7%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 82nd pctile, median 70 · Small: 90th pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 70.7%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 2%.
- ▸10 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 36.90
- P/B
- 4.20
- EV/EBITDA
- 35.81
- Market Cap
- 3435.00Cr
Profitability
- ROE
- 11.60%
- ROCE
- 16.20%
- ROA
- 9.51%
- Dividend Y
- 1.80%
Growth (CAGR)
- Revenue 5Y
- -1.00%
- EPS 5Y
- 35.00%
- Revenue 3Y
- -2.00%
- EPS 3Y
- -3.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 94.00×
- Altman Z
- 8.13
- Book Value
- 331.00
Cash Flow
- FCF Yield
- 1.89%
- FCF Positive Y
- 10/5
- OCF
- 47.00 Cr
- EPS TTM
- 37.74
Shareholding
- Promoter Hold
- 70.68%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 76%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.